Kişilik Bozukluklarının Tanımı ve Psikofarmakolojik Tedavi Yaklaşımları
Özet
Kişilik, bireyin çevreyle etkileşimini ve uyumunu belirleyen tutarlı psikolojik özellikler bütünüdür; mizaç ise erken dönemden itibaren biyolojik temelli eğilimleri ifade eder. Tarihsel süreçte antik çağlardan beri merak uyandıran bu kavram, modern psikiyatride Kraepelin ve Freud gibi isimlerle şekillenmiş ve DSM kılavuzlarında eksenli sistemlerden günümüzdeki tanı kriterlerine evrilmiştir. DSM-V’e göre kişilik bozukluğu, kişinin kültüründen belirgin sapan, biliş, duygulanım, kişilerarası işlevsellik veya dürtü denetimi alanlarında kendini gösteren, işlevselliği bozan süregiden bir davranış örüntüsüdür ve A, B, C olmak üzere üç kümeye (10 farklı bozukluk) ayrılır. Toplumda görülme sıklığı %7.8 civarında olan bu bozuklukların tedavisinde tarihsel olarak psikoterapiler güçlü kanıtlarla vazgeçilmez bir yer tutmaktadır; ancak ulaşılabilirlik sorunları nedeniyle farmakolojik yaklaşımlar da yoğun şekilde araştırılmaktadır. Günümüzde FDA onaylı bir ilaç bulunmadığından tedaviler semptomlara yönelik ve "etiket dışı" olarak yürütülür; ilaç çalışmaları en çok intihar, agresyon ve dürtüselliğin sık görüldüğü B kümesine (özellikle sınırda kişilik bozukluğuna) odaklanır. A kümesinde risperidon ve olanzapin, B kümesinde duygu dengeleyiciler ve atipik antipsikotikler öfke ile agresyon üzerinde etki gösterirken, antidepresanların etkinliği sınırlıdır. İlaçlar tek başına yetersiz olup, komorbid psikiyatrik durumların (depresyon, anksiyete, madde kullanımı vb.) yönetimi ve psikoterapiye ek olarak incelikle planlanmalıdır.
Personality is the sum of consistent psychological characteristics that determine an individual's interaction and adaptation with the environment, while temperament refers to biologically based tendencies from early periods. Intrigued since ancient times, this concept has been shaped in modern psychiatry by figures like Kraepelin and Freud, evolving from axial systems to current diagnostic criteria in DSM manuals. According to DSM-V, a personality disorder is an enduring pattern of behavior that deviates markedly from cultural expectations, manifesting in cognition, affectivity, interpersonal functioning, or impulse control, and is divided into three clusters (10 distinct disorders) that impair functioning. Although psychotherapies hold an indispensable place with strong evidence in the treatment of these disorders, which have a community prevalence of around 7.8%, pharmacological approaches are also intensively researched due to accessibility issues. Since there is currently no FDA-approved medication, treatments are conducted off-label for specific symptoms, and drug trials mostly focus on Cluster B (particularly borderline personality disorder), where suicide, aggression, and impulsivity are frequent. While risperidon and olanzapine show efficacy in Cluster A, and mood stabilizers and atypical antipsychotics reduce anger and aggression in Cluster B, the efficacy of antidepressants remains limited. Medications alone are insufficient and must be carefully planned as an adjunct to psychotherapy and the management of comorbid psychiatric conditions such as depression, anxiety, and substance use.
Referanslar
Mayer JD. Asserting the definition of personality. The online newsletter for personality science. 2007;1(1): 1–4.
Shiner RL, Buss KA, McClowry SG, et al. What Is Temperament Now? Assessing Progress in Temperament Research on the Twenty-Fifth Anniversary of Goldsmith et al. (). Child Development Perspectives. 2012; n/a-n/a. doi:10.1111/j.1750-8606.2012.00254.x
Crocq MA. Milestones in the history of personality disorders. Dialogues in Clinical Neuroscience. 2013;15(2): 147–153. doi:10.31887/dcns.2013.15.2/macrocq
Schultz DP, Schultz SE. Theories of personality.. 8th editio. Belmont: Wadsworth; 2005.
Hendriks A a. J, Hofstee WK., Raad B De. The Five-Factor Personality Inventory (FFPI). Personality and Individual Differences. 1999;27(2): 307–325. doi:10.1016/S0191-8869(98)00245-1
Blashfield RK, Keeley JW, Flanagan EH, et al. The Cycle of Classification: DSM-I Through DSM-5. Annual Review of Clinical Psychology. 2014;10(1): 25–51. doi:10.1146/annurev-clinpsy-032813-153639
Zachar P, Krueger RF, Kendler KS. Personality disorder in DSM-5: An oral history. Psychological Medicine. 2016;46(1): 1–10. doi:10.1017/S0033291715001543
Birliği AP. DSM-5 Tanı Ölçütleri Başvuru Elkitabı. 2013.
Winsper C, Bilgin A, Thompson A, et al. The prevalence of personality disorders in the community: a global systematic review and meta-analysis. The British Journal of Psychiatry. 2020;216(2): 69–78. doi:10.1192/bjp.2019.166
Paris J. Effectiveness of Different Psychotherapy Approaches in the Treatment of Borderline Personality Disorder. Current Psychiatry Reports. 2010;12(1): 56–60. doi:10.1007/s11920-009-0083-0
Gabbard GO. Combining medication with psychotherapy in the treatment of personality disorders. In: Gunderson J, Gabbard GO (eds.) Psychotherapy for personality disorders. Washington, D.C.: American Psychiatric Press, Inc.; 2000. p. 65–94.
Paris J. Pharmacological treatments for personality disorders. International Review of Psychiatry. 2011;23(3): 303–309. doi:10.3109/09540261.2011.586993
Nosè M, Cipriani A, Biancosino B, et al. Efficacy of pharmacotherapy against core traits of borderline personality disorder: Meta-analysis of randomized controlled trials. International Clinical Psychopharmacology. 2006;21(6): 345–353. doi:10.1097/01.yic.0000224784.90911.66
Ingenhoven T, Lafay P, Rinne T, et al. Effectiveness of Pharmacotherapy for Severe Personality Disorders. The Journal of Clinical Psychiatry. 2010;71(01): 14–25. doi:10.4088/JCP.08r04526gre
Birkeland SF. Psychopharmacological treatment and course in paranoid personality disorder. International Clinical Psychopharmacology. 2013;28(5): 283–285. doi:10.1097/YIC.0b013e328363f676
Koch J, Modesitt T, Palmer M, et al. Review of pharmacologic treatment in cluster A personality disorders. Mental Health Clinician. 2016;6(2): 75–81. doi:10.9740/mhc.2016.03.75
Triebwasser J, Chemerinski E, Roussos P, et al. Schizoid Personality Disorder. Journal of Personality Disorders. 2012;26(6): 919–926. doi:10.1521/pedi.2012.26.6.919
Kirchner SK, Roeh A, Nolden J, et al. Diagnosis and treatment of schizotypal personality disorder: evidence from a systematic review. npj Schizophrenia. 2018;4(1): 20. doi:10.1038/s41537-018-0062-8
Koenigsberg HW, Reynolds D, Goodman M, et al. Risperidone in the Treatment of Schizotypal Personality Disorder. The Journal of Clinical Psychiatry. 2003;64(6): 628–634. doi:10.4088/JCP.v64n0602
Rybakowski JK, Dróżdż W, Borkowska A. Low Dose Risperidone in the Treatment of Schizophrenia-Like Symptoms in High-Risk Subjects. Journal of Clinical Psychopharmacology. 2003;23(6): 674–675. doi:10.1097/01.jcp.0000095352.32154.e1
Keshavan MS. Efficacy and tolerability of olanzapine in the treatment of schizotypal personality disorder. Schizophrenia Research. 2004;71(1): 97–101. doi:10.1016/j.schres.2003.12.008
Bogetto F, Bellino S, Vaschetto P, et al. Olanzapine augmentation of fluvoxamine-refractory obsessive–compulsive disorder (OCD): a 12-week open trial. Psychiatry Research. 2000;96(2): 91–98. doi:10.1016/S0165-1781(00)00203-1
Baer L, Jenike MA, Black DW, et al. Effect of Axis II Diagnoses on Treatment Outcome With Clomipramine in 55 Patients With Obsessive-Compulsive Disorder. Archives of General Psychiatry. 1992;49(11): 862. doi:10.1001/archpsyc.1992.01820110026003
Rosell DR, Zaluda LC, McClure MM, et al. Effects of the D1 Dopamine Receptor Agonist Dihydrexidine (DAR-0100A) on Working Memory in Schizotypal Personality Disorder. Neuropsychopharmacology. 2015;40(2): 446–453. doi:10.1038/npp.2014.192
Kraus G, Reynolds DJ. The “a-b-c’s” of the cluster b’s. Clinical Psychology Review. 2001;21(3): 345–373. doi:10.1016/S0272-7358(99)00052-5
Young C, Habarth J, Bongar B, et al. Disorder in the Court: Cluster B Personality Disorders in United States Case Law. Psychiatry, Psychology and Law. 2018;25(5): 706–723. doi:10.1080/13218719.2018.1474816
van den Bosch LMC, Rijckmans MJN, Decoene S, et al. Treatment of antisocial personality disorder: Development of a practice focused framework. International Journal of Law and Psychiatry. 2018;58: 72–78. doi:10.1016/j.ijlp.2018.03.002
Wilson HA. Can Antisocial Personality Disorder Be Treated? A Meta-Analysis Examining the Effectiveness of Treatment in Reducing Recidivism for Individuals Diagnosed with ASPD. International Journal of Forensic Mental Health. 2014;13(1): 36–46. doi:10.1080/14999013.2014.890682
Khalifa NR, Gibbon S, Völlm BA, et al. Pharmacological interventions for antisocial personality disorder. Cochrane Database of Systematic Reviews. 2020;2020(9). doi:10.1002/14651858.CD007667.pub3
Hirose S. Effective treatment of aggression and impulsivity in antisocial personality disorder with risperidone. Psychiatry and Clinical Neurosciences. 2001;55(2): 161–162. doi:10.1046/j.1440-1819.2001.00805.x
Brown D, Larkin F, Sengupta S, et al. Clozapine: an effective treatment for seriously violent and psychopathic men with antisocial personality disorder in a UK high-security hospital. CNS Spectrums. 2014;19(5): 391–402. doi:10.1017/S1092852914000157
Stanford MS, Helfritz LE, Conklin SM, et al. A Comparison of Anticonvulsants in the Treatment of Impulsive Aggression. Experimental and Clinical Psychopharmacology. 2005;13(1): 72–77. doi:10.1037/1064-1297.13.1.72
Konstenius M, Jayaram‐Lindström N, Guterstam J, et al. Methylphenidate for attention deficit hyperactivity disorder and drug relapse in criminal offenders with substance dependence: a 24‐week randomized placebo‐controlled trial. Addiction. 2014;109(3): 440–449. doi:10.1111/add.12369
Paton C, Crawford MJ, Bhatti SF, et al. The Use of Psychotropic Medication in Patients With Emotionally Unstable Personality Disorder Under the Care of UK Mental Health Services. The Journal of Clinical Psychiatry. 2015;76(04): e512–e518. doi:10.4088/JCP.14m09228
Gartlehner G, Crotty K, Kennedy S, et al. Pharmacological Treatments for Borderline Personality Disorder: A Systematic Review and Meta-Analysis. [Online] CNS Drugs. 2021. p. 1053–1067. doi:10.1007/s40263-021-00855-4
Zanarini MC, Schulz SC, Detke HC, et al. A Dose Comparison of Olanzapine for the Treatment of Borderline Personality Disorder. The Journal of Clinical Psychiatry. 2011;72(10): 1353–1362. doi:10.4088/JCP.08m04138yel
Black DW, Zanarini MC, Romine A, et al. Comparison of Low and Moderate Dosages of Extended-Release Quetiapine in Borderline Personality Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial. American Journal of Psychiatry. 2014;171(11): 1174–1182. doi:10.1176/appi.ajp.2014.13101348
Crawford MJ, Sanatinia R, Barrett B, et al. The Clinical Effectiveness and Cost-Effectiveness of Lamotrigine in Borderline Personality Disorder: A Randomized Placebo-Controlled Trial. American Journal of Psychiatry. 2018;175(8): 756–764. doi:10.1176/appi.ajp.2018.17091006
Moen R, Freitag M, Miller M, et al. Efficacy of extended-release divalproex combined with ‘condensed’ dialectical behavior therapy for individuals with borderline personality disorder. Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists. 2012;24(4): 255–260. http://www.ncbi.nlm.nih.gov/pubmed/23145381
Nickel MK, Nickel C, Kaplan P, et al. Treatment of aggression with topiramate in male borderline patients: A double-blind, placebo-controlled study. Biological Psychiatry. 2005;57(5): 495–499. doi:10.1016/j.biopsych.2004.11.044
Tritt K, Nickel C, Lahmann C, et al. Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study. Journal of Psychopharmacology. 2005;19(3): 287–291. doi:10.1177/0269881105051540
Reich DB, Zanarini MC, Bieri KA. A preliminary study of lamotrigine in the treatment of affective instability in borderline personality disorder. International Clinical Psychopharmacology. 2009; 1. doi:10.1097/YIC.0b013e32832d6c2f
Loew TH, Nickel MK, Muehlbacher M, et al. Topiramate Treatment for Women With Borderline Personality Disorder. Journal of Clinical Psychopharmacology. 2006;26(1): 61–66. doi:10.1097/01.jcp.0000195113.61291.48
Zanarini MC, Frankenburg FR, Parachini EA. A Preliminary, Randomized Trial of Fluoxetine, Olanzapine, and the Olanzapine-Fluoxetine Combination in Women With Borderline Personality Disorder. The Journal of Clinical Psychiatry. 2004;65(7): 903–907. doi:10.4088/JCP.v65n0704
Van den Eynde F, Senturk V, Naudts K, et al. Efficacy of Quetiapine for Impulsivity and Affective Symptoms in Borderline Personality Disorder. Journal of Clinical Psychopharmacology. 2008;28(2): 147–155. doi:10.1097/JCP.0b013e318166c4bf
Rocca P, Marchiaro L, Cocuzza E, et al. Treatment of Borderline Personality Disorder With Risperidone. The Journal of Clinical Psychiatry. 2002;63(3): 241–244. doi:10.4088/JCP.v63n0311
M. R, M. S. Off-label use of atypical antipsychotics in personality disorders. Expert Opinion on Pharmacotherapy. 2012;13(11): 1575–1585. http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed10&NEWS=N&AN=2012408720
French JH, Shrestha S. Histrionic Personality Disorder. [Online] StatPearls. 2022. http://www.ncbi.nlm.nih.gov/pubmed/31194465
Dhawan N, Kunik ME, Oldham J, et al. Prevalence and treatment of narcissistic personality disorder in the community: a systematic review. Comprehensive Psychiatry. 2010;51(4): 333–339. doi:10.1016/j.comppsych.2009.09.003
Teusch L, Böhme H, Finke J, et al. Effects of Client-Centered Psychotherapy for Personality Disorders Alone and in Combination with Psychopharmacological Treatment. Psychotherapy and Psychosomatics. 2001;70(6): 328–336. doi:10.1159/000056273
Roepke S, Merkl A, Dams A, et al. Preliminary Evidence of Improvement of Depressive Symptoms but not Impulsivity in Cluster B Personality Disorder Patients Treated with Quetiapine: an Open Label Trial. Pharmacopsychiatry. 2008;41(05): 176–181. doi:10.1055/s-2008-1076730
Lampe L, Malhi G. Avoidant personality disorder: current insights. Psychology Research and Behavior Management. 2018;Volume 11: 55–66. doi:10.2147/PRBM.S121073
Herpertz SC, Zanarini M, Schulz CS, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Personality Disorders. The World Journal of Biological Psychiatry. 2007;8(4): 212–244. doi:10.1080/15622970701685224
Nordahl HM, Vogel PA, Morken G, et al. Paroxetine, Cognitive Therapy or Their Combination in the Treatment of Social Anxiety Disorder with and without Avoidant Personality Disorder: A Randomized Clinical Trial. Psychotherapy and Psychosomatics. 2016;85(6): 346–356. doi:10.1159/000447013
Faith C. Dependent Personality Disorder: A Review of Etiology and Treatment. Graduate Journal of Counseling Psychology. 2009;1(2): 7.
Eskedal GA, Demetri JM. Etiology and Treatment of Cluster C Personality Disorders. Journal of Mental Health Counseling. 2006;28(1): 1–17. doi:10.17744/mehc.28.1.7yjq6tabcexb1a6j
Simonelli A, Parolin M. Dependent Personality Disorder. Encyclopedia of Personality and Individual Differences. Cham: Springer International Publishing; 2017. p. 1–11. doi:10.1007/978-3-319-28099-8_578-1
Diedrich A, Voderholzer U. Obsessive–Compulsive Personality Disorder: a Current Review. Current Psychiatry Reports. 2015;17(2): 2. doi:10.1007/s11920-014-0547-8
Greve KW, Adams D. Treatment of features of Obsessive-Compulsive Personality Disorder using carbamazepine. Psychiatry and Clinical Neurosciences. 2002;56(2): 207–208. doi:10.1046/j.1440-1819.2002.00946.x
Ansseau M, Troisfontaines B, Papart P, et al. Compulsive personality as predictor of response to serotoninergic antidepressants. BMJ. 1991;303(6805): 760–761. doi:10.1136/bmj.303.6805.760
Ekselius L, von Knorring L. Ekselius, L.; von Knorring, L.. Personality disorder comorbidity with major depression and response to treatment with sertraline or citalopram. International Clinical Psychopharmacology: September 1998 - Volume 13 - Issue 5 - p 205-212. International Clinical Psychopharmacology. 1998;13(5): 205–212. doi:10. 1097/00004850-199809000-00003.
Cavedini P, Erzegovesi S, Ronchi P, et al. Predictive value of Obsessive–Compulsive Personality Disorder in antiobsessional pharmacological treatment. European Neuropsychopharmacology. 1997;7(1): 45–49. doi:10.1016/S0924-977X(96)00382-3
Gazzillo F, Dazzi N, Kealy D, et al. Personalizing psychotherapy for personality disorders: Perspectives from control-mastery theory. Psychoanalytic Psychology. 2021;38(4): 266–278. doi:10.1037/pap0000295
Lenzenweger MF, Lane MC, Loranger AW, et al. DSM-IV Personality Disorders in the National Comorbidity Survey Replication. Biological Psychiatry. 2007;62(6): 553–564. doi:10.1016/j.biopsych.2006.09.019
Van HL, Kool M. What we do, do not, and need to know about comorbid depression and personality disorders. The Lancet Psychiatry. 2018;5(10): 776–778. doi:10.1016/S2215-0366(18)30260-8
Shah R, Zanarini MC. Comorbidity of Borderline Personality Disorder. Psychiatric Clinics of North America. 2018;41(4): 583–593. doi:10.1016/j.psc.2018.07.009
Parmar A, Kaloiya G. Comorbidity of Personality Disorder among Substance Use Disorder Patients: A Narrative Review. Indian Journal of Psychological Medicine. 2018;40(6): 517–527. doi:10.4103/IJPSYM.IJPSYM_164_18
Ralevski E, Ball S, Nich C, et al. The Impact of Personality Disorders on Alcohol-Use Outcomes in a Pharmacotherapy Trial for Alcohol Dependence and Comorbid Axis I Disorders. American Journal on Addictions. 2007;16(6): 443–449. doi:10.1080/10550490701643336
Gianoli MO, Jane JS, O’Brien E, et al. Treatment for comorbid borderline personality disorder and alcohol use disorders: A review of the evidence and future recommendations. Experimental and Clinical Psychopharmacology. 2012;20(4): 333–344. doi:10.1037/a0027999
Rosenvinge JH, Martinussen M, Østensen E. The comorbidity of eating disorders and personality disorders: A metaanalytic review of studies published between 1983 and 1998. Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity. 2000;5(2): 52–61. doi:10.1007/BF03327480
Martinussen M, Friborg O, Schmierer P, et al. The comorbidity of personality disorders in eating disorders: a meta-analysis. Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity. 2017;22(2): 201–209. doi:10.1007/s40519-016-0345-x
Philipsen A. Differential diagnosis and comorbidity of attention-deficit/hyperactivity disorder (ADHD) and borderline personality disorder (BPD) in adults. European Archives of Psychiatry and Clinical Neuroscience. 2006;256(S1): i42–i46. doi:10.1007/s00406-006-1006-2
Storebø OJ, Simonsen E. The Association Between ADHD and Antisocial Personality Disorder (ASPD). Journal of Attention Disorders. 2016;20(10): 815–824. doi:10.1177/1087054713512150
Matthies S, Philipsen A. Comorbidity of Personality Disorders and Adult Attention Deficit Hyperactivity Disorder (ADHD)—Review of Recent Findings. Current Psychiatry Reports. 2016;18(4): 33. doi:10.1007/s11920-016-0675-4
Stoffers-Winterling J, Storebø OJ, Lieb K. Pharmacotherapy for Borderline Personality Disorder: an Update of Published, Unpublished and Ongoing Studies. Current Psychiatry Reports. 2020;22(8): 37. doi:10.1007/s11920-020-01164-1
